Project Grant R21CA292221
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$503K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Seattle Children's Hospital to conduct a Phase 2 clinical trial testing the efficacy of B7-H3 chimeric antigen receptor (CAR) T-cell therapy for children and young adults with diffuse intrinsic pontine glioma (DIPG), a fatal central nervous system tumor. The $456,414 award, effective June 1, 2025 through April 30, 2030, will support the development of advanced neuroimaging...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to support research aimed at improving engineered T cell receptor T cell (TCR-T) therapy for solid tumors. The key objectives are to: 1) Determine why engineered TCR-T cells form a different stem-like reservoir population in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,880 in funding to the Fred Hutchinson Cancer Center in Seattle, WA to develop a new cancer treatment approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can specifically target the tumor microenvironment and activate other immune cells to attack solid tumors, particularly in patients with melanoma and other cancers resistant to current immunotherapies....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel combination of high linear energy transfer (high-LET) radiotherapies for the treatment of relapsed and refractory neuroblastoma. The award totals $600,079 and runs from September 17, 2024 to August 31, 2029. The key products/services to be delivered include: Developing two new high-LET radiotherapies - 77Br-MBBG (Auger-emitting) targeting the norepinephrine...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand (NP855) for the treatment of high-risk neuroblastoma. NP855 is designed to target the integrin αvβ3 receptor and norepinephrine transporter, which are overexpressed in neuroblastoma cells. The funding will support scaled-up manufacturing, in vitro and in vivo efficacy evaluation, and...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to investigate tumor and immune signatures associated with disparities in outcomes for patients with high-risk neuroblastoma following GD2 immunotherapy. The total funding amount is $576,659.00 and the award start date is July 2, 2024. The key objectives of this research project are to: 1) Perform single-cell genomic, proteomic, and functional...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $225,101 to Baylor College of Medicine to conduct research aimed at understanding how the MYCN oncogene drives an immune-suppressive tumor microenvironment in neuroblastoma. The key objectives are to: 1) determine how MYCN rewires T cell metabolism to promote immune suppression, and 2) elucidate how MYCN-induced lipogenesis contributes to a suppressive tumor immune...
This federal Cooperative Agreement award of $1,390,720.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to develop novel, targeted chimeric antigen receptor (CAR) T-cell therapies for the treatment of medulloblastoma, a deadly pediatric brain cancer. The project aims to optimize the potency of GPC2-targeted CAR T-cells by overexpressing the transcription factor c-Jun, with the goal of improving long-term disease control...
This federal Project Grant award of $399,669.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research program) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for the treatment of glioblastoma (GBM), the most common and deadly primary brain cancer. The key products/services to be delivered under this award include: Developing a platform to generate potent and personalized GBM-specific T cells in an...